High Court Snub To Teva Labeling Case Puts Focus On FDA
The U.S. Supreme Court's decision Tuesday not to review a challenge by generics makers including Teva Pharmaceuticals USA Inc. to failure-to-update labeling claims effectively puts the future of such suits in...To view the full article, register now.
Already a subscriber? Click here to view full article